RxDoctor Payments Data

John Lawrence, OD

Optometrist · Muncie, INNPI 1609438423

Payments from drug & device makers

$1,768in general payments, 2019–2025

Across 58 payments — averaging $30.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$491
  • ANI Pharmaceuticals, Inc.$227
  • Ocular Therapeutix, Inc.$209
  • Lumenis BE Inc$160
  • Dompe US, Inc.$118
  • Rayner Intraocular Lenses Limited$110
  • plus $455 from 13 others

What the payments were for

  • Food & beverage$1,768100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,768 in reported general payments places this provider in the 75th percentile of 1,318 optometrist providers in Indiana.

See all optometrist providers in Indiana

Medicare billing

Part B allowed, 2024
$8,211
Medicare patients
64
Services billed
118

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast19$35,708
XdemvyLotilaner17$31,316
RestasisCyclosporine18$12,303
Brimonidine Tartrate35$4,435
Latanoprost217$2,634
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat64$1,226
Dorzolamide Hcl35$1,223
Prednisolone Acetate29$756
Ketorolac Tromethamine22$326
ErythromycinErythromycin Base16$196
Cephalexin21$128
Timolol Maleate15$118

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra$45$35,70819 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$36$31,31617 claims
AbbVieRestasis$61$12,30318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,318 optometrist providers in Indiana.

Other optometrist in Muncie

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →